Literature DB >> 20879831

Lipid goals among patients with diabetes or metabolic syndrome: Lipid Treatment Assessment Project (L-TAP) 2.

J Wouter Jukema1, Cheng-Wen Chiang, Jean Ferrières, Raul D Santos, Juan Verdejo, David D Waters, Michael Messig, Lisa Tarasenko.   

Abstract

OBJECTIVE: This analysis of the Lipid Treatment Assessment Project 2 population compared lipid goal attainment by diabetes and metabolic syndrome status. RESEARCH DESIGN AND METHODS: Dyslipidaemic patients aged ≥ 20 years on stable lipid lowering therapy had their lipid levels determined once during enrolment at investigation sites in nine countries between September 2006 and April 2007. Achievement of low-density lipoprotein (LDL) cholesterol success, triglycerides < 150 mg/dl (1.7 mmol/l), and high-density lipoprotein (HDL) cholesterol success (> 40 mg/dl [1.0 mmol/l] in men or > 50 mg/dl [1.3 mmol/l] in women) was compared using logistic regression.
RESULTS: A total of 9955 patients were evaluated. Patients with diabetes, compared with those without diabetes, had lower achievement of LDL cholesterol goals (according to National Cholesterol Education Program Adult Treatment Panel [NCEP ATP] III guidelines; 67% vs. 75%), triglycerides < 150 mg/dl (55% vs. 64%), and HDL cholesterol success (61% vs. 74%; p < 0.0001 for all comparisons). The significantly lower lipid goal attainment in patients with diabetes was consistent across participating world regions. Patients with metabolic syndrome, compared with those without metabolic syndrome, had lower achievement of NCEP ATP III LDL cholesterol goals (69% vs. 76%), triglycerides < 150 mg/dl (36% vs. 83%), and HDL cholesterol success (49% vs. 89%; p < 0.0001 for all comparisons). As the number of metabolic syndrome components increased, lipid success rates progressively decreased (p < 0.0001 for LDL cholesterol success, triglycerides < 150 mg/dl, and HDL cholesterol success).
CONCLUSIONS: This analysis indicates that despite their increased cardiovascular risk, patients with diabetes or metabolic syndrome remain undertreated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20879831     DOI: 10.1185/03007995.2010.522490

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia.

Authors:  Michael M Mendelson; Todd Regh; James Chan; Annette Baker; Heather Harker Ryan; Nicole Palumbo; Philip K Johnson; Suzanne Griggs; Meera Boghani; Nirav K Desai; Elizabeth Yellen; Lucy Buckley; Matthew W Gillman; Justin P Zachariah; Dionne Graham; Sarah D de Ferranti
Journal:  J Pediatr       Date:  2016-08-31       Impact factor: 4.406

Review 2.  Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs?

Authors:  Timothy J Shoemaker; Tatsuyoshi Kono; Cary N Mariash; Carmella Evans-Molina
Journal:  Endocr Pract       Date:  2012 Nov-Dec       Impact factor: 3.443

Review 3.  LDL cholesterol goals in high-risk patients: how low do we go and how do we get there?

Authors:  Joost Besseling; Julian van Capelleveen; John J P Kastelein; G Kees Hovingh
Journal:  Drugs       Date:  2013-03       Impact factor: 9.546

Review 4.  Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

Authors:  Robert S Rosenson; R Scott Wright; Michael Farkouh; Jorge Plutzky
Journal:  Am Heart J       Date:  2012-10-16       Impact factor: 4.749

5.  Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US.

Authors:  Elizabeth Marrett; Changgeng Zhao; Ning Jackie Zhang; Qiaoyi Zhang; Dena R Ramey; Joanne E Tomassini; Andrew M Tershakovec; David R Neff
Journal:  Vasc Health Risk Manag       Date:  2014-04-25

6.  Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Authors:  Peter H Jones; Radhika Nair; Kamlesh M Thakker
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.